论文部分内容阅读
Background: So far, no PDE4 inhibitors in Alzheimers disease has been approved for application in the clinic due to severe side effects such as nausea and vomiting.Objective: In this study, we investigated the effect of roflupram, a novel PDE4 inhibitor, on learning and memory ability as well as the underlying mechanism in APP/PS1 mouse model of Alzheimers disease.